Efficacy and Safety of Temporal Interference Stimulation in Treatment-Resistant Schizophrenia: An Exploratory Study.
This exploratory study aims to evaluate the preliminary efficacy and safety of temporal interference (TI) stimulation in patients with treatment-resistant schizophrenia (TRS). TI is a noninvasive brain stimulation technique that uses two high-frequency electrical currents with slightly different frequencies to generate a lower-frequency modulation at a targeted deep brain region.
A total of 20 patients with TRS will receive 130-Hz TI stimulation targeting the anterior limb of the internal capsule (ALIC). Stimulation will be delivered at a total current intensity of 4 mA for 5 consecutive days, with four 40-minute sessions per day. Participants will continue their stable antipsychotic medication regimen during the study.
Clinical symptoms, cognitive function, social functioning, and safety will be assessed before treatment, after completion of the 5-day treatment course, and at a 2-week follow-up. The primary clinical outcome is the change in the Positive and Negative Syndrome Scale (PANSS) total score. Secondary assessments include PANSS subscale scores, the MATRICS Consensus Cognitive Battery (MCCB), Calgary Depression Scale for Schizophrenia (CDSS), Personal and Social Performance Scale (PSP), and Clinical Global Impression (CGI). Safety will be evaluated through daily monitoring of treatment-related discomfort and adverse events.
Magnetic resonance imaging (MRI) will also be performed before and after treatment to explore treatment-related changes in brain structure, functional activity, functional connectivity, activation, and cerebral blood flow. The study hypothesizes that TI stimulation targeting the ALIC may improve clinical symptoms in patients with TRS and may be associated with measurable changes in neuroimaging markers.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Right-handed male or female participants aged 18 to 65 years, inclusive.
- Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), established by a psychiatrist at the attending-physician level or above and confirmed by the Mini International Neuropsychiatric Interview, version 7.0.2 (MINI 7.0.2).
- Inadequate response to sequential treatment with at least two antipsychotic medications of different chemical classes, each administered at an adequate dose (≥600 mg/day chlorpromazine equivalents) for an adequate duration (≥6 consecutive weeks at a therapeutic dose).
- Stable dose of antipsychotic medication for at least 4 weeks before enrollment.
- A score of 4 (moderate) or higher on at least two of the following Positive and Negative Syndrome Scale (PANSS) items: delusions, hallucinatory behavior, suspiciousness/persecution, or unusual thought content.
- Ability to understand the study procedures, willingness to participate voluntarily and comply with the study procedures, and provision of written informed consent.
Exclusion Criteria:
- Current diagnosis of another major psychiatric disorder other than schizophrenia that, in the investigator's judgment, may confound the diagnosis of schizophrenia or interfere with the assessment of treatment efficacy or safety.
- Receipt of other neuromodulation treatments, including modified electroconvulsive therapy (MECT), repetitive transcranial magnetic stimulation (rTMS), or transcranial direct current stimulation (tDCS), within the previous 3 months, or previous participation in an interventional clinical trial involving vagus nerve stimulation (VNS) or deep brain stimulation (DBS).
- A score ≥3 on Item 3 (suicide) of the 17-item Hamilton Depression Rating Scale (HAMD-17), or a score >3 on any of the following PANSS items: P4 Excitement, G14 Poor Impulse Control, P7 Hostility, or G8 Uncooperativeness.
- Contraindications to magnetic resonance imaging (MRI), including intracranial metallic implants, implanted cardiac pacemakers, or cochlear implants.
- Skull defects or fissures, or inability to tolerate stimulation-related adverse effects.
- Treatment-resistant epilepsy or other serious medical conditions that, in the investigator's judgment, may potentially affect treatment or participation in the study.
- Pregnancy.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Stimolazione a Interferenza Temporale
|
Participants with treatment-resistant schizophrenia will receive 130-Hz temporal interference stimulation targeting the anterior limb of the internal capsule (ALIC).
Stimulation will be delivered at a total current intensity of 4 mA for 5 consecutive days, with four 40-minute sessions per day and a 20-minute interval between sessions.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment
Lasso di tempo: Baseline to Day 5
|
Baseline to Day 5
|
|
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 2-Week Follow-up
Lasso di tempo: Baseline to Day 14 ± 2 days after treatment completion
|
Baseline to Day 14 ± 2 days after treatment completion
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Change From Baseline in PANSS Positive Symptom Subscale Score
Lasso di tempo: Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
|
Change From Baseline in PANSS Negative Symptom Subscale Score
Lasso di tempo: Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
|
Change From Baseline in PANSS General Psychopathology Subscale Score
Lasso di tempo: Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
|
Change From Baseline in MATRICS Consensus Cognitive Battery (MCCB) Score
Lasso di tempo: Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
|
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Score
Lasso di tempo: Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
|
Change From Baseline in Personal and Social Performance Scale (PSP) Score
Lasso di tempo: Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
|
Change From Baseline in Clinical Global Impression (CGI) Score
Lasso di tempo: Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CapitalMedicalU
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .